Promising new combo aims to control rare melanoma before and after surgery
NCT ID NCT07517653
First seen Apr 16, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests a new combination of drugs (SHR-1701 and famitinib) given before and after surgery for a rare type of skin cancer called mucosal melanoma. The goal is to see if this approach can help keep the cancer from coming back. About 70 adults with resectable tumors will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.